Bronchogen vs DS5
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
BronchogenSleep Optimization
DS5- Summary
- Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
- DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
- Half-Life
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- Estimated 30-60 minutes (peptide degradation)
- Admin Route
- SubQ, Oral
- Subcutaneous, Intranasal (research)
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 200-500 mcg per dose
- Frequency
- Daily for 10–30 days
- Once nightly
- Key Benefits
- Tissue-specific support for bronchial and lung health
- Promotes normalization of bronchial epithelial cell function
- Potential benefits in chronic bronchitis and COPD support
- Anti-aging effects on pulmonary tissue
- May reduce frequency of respiratory infections
- Supports lung function preservation with aging
- Compatible with other Khavinson bioregulator peptides
- Promotes delta-wave (deep) sleep and improves sleep quality
- May reduce sleep onset latency
- HPA axis modulation for stress reduction
- Non-addictive sleep support without tolerance development
- Potential circadian rhythm normalization
- Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
- Side Effects
- Generally well tolerated in research studies
- Mild local reactions at injection site (if injected)
- No significant systemic side effects reported at standard doses
- Generally well-tolerated in research subjects
- Possible morning grogginess at higher doses
- Mild blood pressure fluctuations reported with DSIP
- Limited human safety data for DS5 specifically
- Stacks With
- —
- —